 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Bone Cancer - General
|
|
Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone (6/10/2009)
Researchers involved in an international Phase II clinical trial have reported that 86% of patients with giant cell tumor of the bone responded to treatment with denosumab. These results were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on June 1.
Immunostimulant MTP Improves Survival in Pediatric Osteosarcoma (3/5/2008)
Researchers affiliated with the Children’s Oncology Group have shown that the addition of muramyl tripeptide (MTP) to chemotherapy improves survival in patients with osteosarcoma. The details of this study appeared in the February 1, 2008 issue of the Journal of Clinical Oncology.
Not Approvable Letter for Mifamurtide (9/19/2007)
IDM Pharma, Inc. has received a not approvable letter from the United States Food and Drug Administration (FDA) for their investigational drug mifamurtide (L-MTP-PE) – formerly Junovan – for the treatment of osteosarcoma.
Neoadjuvant Chemotherapy Effective for Older Patients with Osteosarcoma (8/6/2007)
Researchers from Italy have reported that neoadjuvant chemotherapy improves prognosis and reduces amputations in patients over 40 years of age with localized osteosarcoma of the extremity. The details of this study appeared in the June, 2007 issue of Acta Orthopedica.
Radium-223 Effective for Hormone Refractory Prostate Cancer and Bone Metastases (7/9/2007)
Researchers from Sweden and Norway have reported that bone-targeted Radium-223 was associated with significant palliation in patients with hormone refractory prostate cancer (HRPC). The details of this randomized trial appeared in the July, 2007 issue of Lancet Oncology.
High-Dose Therapy Confirmed as Effective for Refractory Ewing’s Sarcoma (8/28/2006)
Researchers from the United Kingdom have reported that high-dose chemotherapy with autologous peripheral blood stem cell support results in a five-year event-free survival (EFS) of 38% in patients with relapsed or refractory Ewing’s sarcoma.
Heart Dysfunction Continues Long After Treatment With Adriamycin® (7/25/2006)
Researchers from the Netherlands have reported that childhood cancer survivors with bone cancer who were treated with Adriamycin (doxorubicin) demonstrated declining heart function 22 years following treatment.
Autologous Stem Cell Transplants May Improve Outcomes of Relapsed Ewing’s Sarcoma (8/1/2005)
Researchers from the Fred Hutchinson Cancer Research Center (FHCRC) have reported that high-dose chemotherapy and autologous stem cell transplantation may improve survival in patients with chemotherapy response relapse of Ewing’s sarcoma.
Onyvax-105 Shows Promising Results in Osteosarcoma (5/3/2005)
Researchers affiliated with the UK Children’s Cancer Study Group have reported that a vaccine known as Onyvax-105 (105AD7 ) elicits an immune response in patients with osteosarcoma.
Localized Pelvic Ewing Sarcoma has a Worse Prognosis Than Localized Involvement of Other Bones (2/20/2003)
The Ewing sarcoma group of tumors occurs in late childhood and early adulthood and involves the bone. Approximately 25% occur in the pelvis and approximately 40% occur in one of the three leg bones. However, it is generally considered that Ewing sarcoma involving the pelvis has a worse prognosis than other sites. This may be due to delay in diagnosis which results in a larger tumor size at presentation. In the February 2003 issue of the
Journal of Pediatric Hematology Oncology, Italian researchers summarized their results of treating 77 patients with pelvic Ewing sarcoma between 1979 and 1996 with a follow-up of over 10 years. None of these patients had distant metastasis at diagnosis.
Surgery Required to Cure Osteosarcoma (11/19/2002)
Osteosarcoma is a relatively rare cancer which occurs in adolescents and young adults. Osteosarcoma usually involves an extremity. Current treatment of osteosarcoma involves initial chemotherapy followed by surgery and then by further consolidative chemotherapy. Surgery usually consists of amputation or extensive local excision. This strategy has led to cure rates of 50-65% compared to cure rates of approximately 20% when surgery alone is used. The success of chemotherapy in improving the cure rate prompted researchers at MD Anderson Cancer Center to evaluate the feasibility of cure by chemotherapy alone. In a study that began in 1978 involving 31 patients, these researchers evaluated chemotherapy alone as treatment for osteosarcoma. They reported their findings in the November 15, 2002 issue of
Cancer.
Ethyol® May Prevent Granulocytopenia in Children Being Treated for Osteosarcoma (5/22/2002)
According to results recently published in the
Journal of Pediatric Hematology-Oncology, Ethyol® (amifostine) decreases the incidence of granulocytopenia in patients undergoing treatment for osteogenic sarcoma.
|
|
Patient Home
